BioCentury
ARTICLE | Clinical News

Syntimmune reports Phase Ia data for autoimmune disease candidate

January 19, 2018 4:56 AM UTC

Syntimmune Inc. (Waltham, Mass.) reported data from a Phase Ia trial in 31 healthy volunteers showing that single ascending doses of IgG-mediated autoimmune disease candidate IV SYNT001 were well tolerated with no serious adverse events reported. The company said SYNT001 also led to rapid, dose-dependent, durable and clinically significant reductions in total IgG levels and in levels of circulating immune complexes. Data were presented at the American Society of Hematology meeting in Atlanta in December.

The double-blind, placebo-controlled, U.S. trial evaluated safety as its primary endpoint. Secondary endpoints include pharmacodynamics and pharmacokinetics...